Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515697 · ClinicalTrials.gov registry record · Phase 2
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
A Phase 2 study of Metastatic Renal Cell Carcinoma, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 11
- Study locations
NCT00515697 is a Phase 2 study of Metastatic Renal Cell Carcinoma that has completed, run by Eli Lilly and Company. The registered enrollment target is 39 participants, below the 142-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT00515697, a Phase 2 study of Metastatic Renal Cell Carcinoma, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor therapy.
Conditions Studied
Interventions
- BIOLOGICAL Ramucirumab
Study Locations (11)
Pennsylvania
- ImClone Investigational Site - Drexel Hill
- ImClone Investigational Site - Philadelphia
California
- ImClone Investigational Site - San Francisco
Illinois
- ImClone Investigational Site - Chicago
Louisiana
- ImClone Investigational Site - Metairie
Massachusetts
- ImClone Investigational Site - Boston
New Jersey
- ImClone Investigational Site - Flemington
New York
- ImClone Investigational Site - Buffalo
Ohio
- ImClone Investigational Site - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515697
The ClinicalTrials.gov registry entry for NCT00515697 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Ramucirumab is the first listed.
NCT00515697 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Pennsylvania, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00515697 about?
NCT00515697 is a clinical study titled "A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma". The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor therapy.
What is the current status of trial NCT00515697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2007-11. Estimated completion is 2011-05.
What conditions does trial NCT00515697 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT00515697?
The interventions under investigation include: Ramucirumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00515697?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00515697 being conducted?
This trial has 11 study locations across California, Illinois, Louisiana, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.